About IBB ETF
Biotechnology is the 'next big thing' in the technology sector. The Blackrock Biotechnology ETF (IBB) provides targeted exposure to equities in the biotechnology and pharmaceuticals sectors trading on the NASDAQ.
| IBB Performance | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| This ETF | 16.38% | 11.25% | 1.99% | 17.54% |
Projected Returns
Returns % (CAGR)based on historic returns of 17.54% per annum
Asset Class
Asset type breakdown
IBB Holdings - Top 10
| Namei | Weightage (%) | |
|---|---|---|
| Amgen Inc | 8.42% | |
| Vertex Pharmaceuticals Incorporated | 8.05% | |
| Gilead Sciences, Inc | 7.88% | |
| Regeneron Pharmaceuticals, Inc | 6.91% | |
| Biogen Inc | 6.16% | |
| Illumina, Inc | 4.31% | |
| Seattle Genetics, Inc | 3.14% | |
| Moderna, Inc | 2.71% | |
| Alexion Pharmaceuticals, Inc | 2.54% | |
| Incyte Corporation | 2.34% |
IBB Sectors/Industry Breakdown
| Sectori | % of market value | |
|---|---|---|
| Healthcare | 99.94% | |
| Basic Materials | 0.06% |
IBB Countries
| Country | % of market value | |
|---|---|---|
| North America | 92.49% | |
| Europe Developed | 3.29% | |
| Asia Emerging | 2.46% | |
| United Kingdom | 1.49% | |
| Asia Developed | 0.16% | |
| Africa/Middle East | 0.11% |
IBB Summary Data
| Fund Size(AUM) | $ | i |
| Avg. mkt. cap (MM) | $ | i |
| Morningstar Ratings | 3 | i |
| Symbol | IBB | |
| Exchange | XNAS |
| ISIN | US4642875565 | |
| Cat. Benchmark | MSCI ACWI NR USD | |
| Asset class | Equity | |
| Category | Health | |
| Country | US |
IBB Portfolio Data & Volatility Analysis
| Expense ratio | 0.47 | i |
| Beta | 0.99 | i |
| P/E ratio | 16.84587 | i |
| Standard Deviation | 22.66 | i |
Fund Strategy
iShares Nasdaq Biotechnology ETF is an exchange-traded fund incorporated in the USA. The Fund's objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index. The Fund will concentrate its investments in companies primarily engaged in using biomedical research for the discovery or development of new treatments or cures for human disease.
IBB Fact Sheets & Reports
ProspectusFactsheetAbout iShares by Blackrock
With more than twenty years of ETF experience, a global line-up of 800+ exchange-traded funds (ETFs) and $1.9 trillion in assets under management, iShares continually strives to unlock new opportunities for our investors. By channeling strategic thinking and expertise into a robust offering of investment funds, iShares aims to make wealth-building easier, more efficient, and more rewarding for all investors.
